First Trust SMID Growth Strength ETF(FSGS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

FSGS First Trust SMID Growth Strength ETF

Market Closed 12-12 16:00:00 EST

31.18

+0.00

0.00%

盘后31.18

+0.000.00%

16:04 EST

High31.18	Low31.18	Vol285.00
Open31.18	D1 Closing31.18	Amplitude0.00%
Mkt Cap31.18M	Tradable Cap31.18M	Total Shares1.00M
T/O8.86K	T/O Rate0.03%	Tradable Shares1.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"FSGS","market":"US","secType":"STK","nameCN":"First Trust SMID Growth Strength ETF","latestPrice":31.1801,"timestamp":1765573200000,"preClose":31.1801,"halted":0,"volume":285,"hourTrading":{"tag":"盘后","latestPrice":31.1801,"preClose":31.1801,"latestTime":"16:04 EST","volume":4,"amount":124.2216,"timestamp":1765573454126},"delay":0,"floatShares":1000002,"shares":1000002,"eps":0,"marketStatus":"Market Closed","change":0,"latestTime":"12-12 16:00:00 EST","open":31.1801,"high":31.1801,"low":31.1801,"amount":8859.008613,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":31.1801,"sharesOutstanding":1000002,"nav":31.18,"aum":31180062.36,"dividendRate":0.012601,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":31.1801,"preClose":31.1801,"latestTime":"16:04 EST","volume":4,"amount":124.2216,"timestamp":1765573454126},"volumeRatio":0.483378520744698},"requestUrl":"/m/hq/s/FSGS/tweets","defaultTab":"tweets","newsList":[{"id":"2588223127","title":"Akebia Announces Establishment of Rare Kidney Disease Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2588223127","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588223127?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590400,"startTime":"0","endTime":"0","summary":"Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease ind","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/01/3196841/37519/en/Akebia-Announces-Establishment-of-Rare-Kidney-Disease-Pipeline.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","PD","BK4218","PK","LU0256331488.USD","BK4181","BK4161","BK4588","MACE","BK4213","IE00BLDYK493.USD","BK4157","BK4585","BK4183","LU1169590202.USD","MI","LU1169589451.USD","FSGS","BK4023","APA","LU2065731478.USD","IE00B64QTZ34.USD","RBC"],"gpt_icon":0},{"id":"2584757249","title":"ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2584757249","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584757249?lang=en_us&edition=fundamental","pubTime":"2025-11-20 05:20","pubTimestamp":1763587200,"startTime":"0","endTime":"0","summary":"ZyVersa is advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies – Cholesterol Efflux Mediator VAR 200 for treatment of kidney diseases, and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/19/3191443/0/en/ZyVersa-Therapeutics-Reports-Third-Quarter-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4539","BK4139","ZVSA","BK4007","FSGS"],"gpt_icon":0},{"id":"2584596023","title":"Dimerix Achieves Positive IDMC Review for Phase 3 FSGS Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2584596023","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584596023?lang=en_us&edition=fundamental","pubTime":"2025-11-19 08:48","pubTimestamp":1763513281,"startTime":"0","endTime":"0","summary":"An update from Dimerix Limited ( ($AU:DXB) ) is now available. Dimerix Limited announced the successful completion of the seventh Independent Data ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/dimerix-achieves-positive-idmc-review-for-phase-3-fsgs-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/dimerix-achieves-positive-idmc-review-for-phase-3-fsgs-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FSGS"],"gpt_icon":0},{"id":"2582224330","title":"A Look at Travere Therapeutics’s Valuation Following Positive Phase 3 FILSPARI Data in FSGS","url":"https://stock-news.laohu8.com/highlight/detail?id=2582224330","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582224330?lang=en_us&edition=fundamental","pubTime":"2025-11-11 13:27","pubTimestamp":1762838842,"startTime":"0","endTime":"0","summary":"Travere Therapeutics (TVTX) just released new findings from its Phase 3 DUPLEX Study, showing that FILSPARI treatment helped FSGS patients achieve meaningful reductions in proteinuria compared to the existing standard of care.\nSee our latest analysis for Travere Therapeutics.\nThe excitement from Travere’s Phase 3 DUPLEX Study update comes after a robust rally for the stock, as the one-month share price return surged 36.7% and the 90-day gain climbed to an impressive 90.5%. Adding to the...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/a-look-at-travere-therapeuticss-valuation-following-positive-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/a-look-at-travere-therapeuticss-valuation-following-positive-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["FSGS","BK4139","TVTX","BK4007","BK4539","LENZ"],"gpt_icon":0},{"id":"2581076953","title":"Dimerix to Benefit from Filpari's Approval, But Nothing to Lose from Rejection, Says Euroz Hartleys","url":"https://stock-news.laohu8.com/highlight/detail?id=2581076953","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581076953?lang=en_us&edition=fundamental","pubTime":"2025-11-07 15:02","pubTimestamp":1762498924,"startTime":"0","endTime":"0","summary":"If Dimerix's  US peer Travere's drug Filspari is approved by the US Food and Drug Administration, it would likely be positive for Dimerix, but the consequences would be neutral if rejected, said Euroz Hartleys in a Friday note.The research firm believes that the Filspari launch would raise awareness of focal segmental glomerulosclerosis , improve diagnosis, and establish insurance support for rare kidney disease treatments, and as doctors are expected to use Dimirex's DMX-200 together with Filspari, it could help accelerate acceptance of the medication.If the US FDA rejects Filspari, the effect would likely be neutral for Dimerix, the note added.Euroz Hartleys said that Travere's setback would stem from its trial design, not the medical need. Dimerix's own placebo-controlled study with clear goals follows a stronger regulatory path, keeping its outlook intact.Euroz Hartleys has maintained its speculative buy rating on Dimerix with a price target of AU$1.68.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","FSGS","BK7501","DXB.AU"],"gpt_icon":0},{"id":"2581779554","title":"Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2581779554","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581779554?lang=en_us&edition=fundamental","pubTime":"2025-11-05 22:15","pubTimestamp":1762352100,"startTime":"0","endTime":"0","summary":"VERO BEACH, Fla., Nov.  05, 2025  (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies and in","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/05/3181589/0/en/Processa-Pharmaceuticals-Announces-Poster-Presentation-of-Adaptive-Phase-2-3-PCS499-Study-in-FSGS-at-ASN-Kidney-Week-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FSGS","NGC"],"gpt_icon":0},{"id":"2579170781","title":"Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2579170781","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579170781?lang=en_us&edition=fundamental","pubTime":"2025-10-30 19:05","pubTimestamp":1761822300,"startTime":"0","endTime":"0","summary":"Generated $459 million in 3Q 2025 revenues, including $178 million in U.S. net product salesReceived 152 new patient start forms for EMPAVELI (pegcetacoplan) in the first two months since launch in C3","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/30/3177251/0/en/Apellis-Pharmaceuticals-Reports-Third-Quarter-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4575","LU1803068979.SGD","LU2054465674.USD","LU1316542783.SGD","IE00B5949003.HKD","IE0009356076.USD","BK4585","LU0823421333.USD","LU0823421416.USD","LU0127658192.USD","LU0642271901.SGD","LU1064131342.USD","LU1951198990.SGD","LU1303367103.USD","LU2360106780.USD","LU1242518857.USD","LU0390134368.USD","LU0056508442.USD","EMA","LU2250418816.HKD","BK4543","BK4534","LU2458330169.SGD","LU0082616367.USD","LU2098885051.SGD","IE0004445239.USD","LU0823434583.USD","BK4554","BK4529","LU0719512351.SGD","LU1852331112.SGD","BK4532","LU0889565833.HKD","LU0823434740.USD","BK4087","LU1988902786.USD","LU1861558580.USD","CHMP","LU1880398471.USD","LU0979878070.USD","BK4573","FSGS","LU1880398554.USD","LU1951200564.SGD","BK4141","LU1242518931.SGD","BK4566","LU0109392836.USD","BK4512"],"gpt_icon":1},{"id":"2577616183","title":"Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET","url":"https://stock-news.laohu8.com/highlight/detail?id=2577616183","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577616183?lang=en_us&edition=fundamental","pubTime":"2025-10-22 20:00","pubTimestamp":1761134400,"startTime":"0","endTime":"0","summary":"BRISBANE, Calif., Oct.  22, 2025  (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treat","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/22/3171023/0/en/Vera-Therapeutics-to-Host-an-Investor-Call-and-Webcast-to-Provide-an-ORIGIN-3-Update-on-November-6-2025-at-4-30-pm-ET.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TACI","LU1732799900.SGD","LU0726765562.USD","IE0004445015.USD","LU1074936037.SGD","LU1244550221.USD","LU1732800096.USD","IE00BFSS8Q28.SGD","VERA","FSGS","LU0795875086.SGD","IE00B7KXQ091.USD","BK4534","ET","LU1585245621.USD","LU1718418525.SGD","LU2133065610.SGD","BK4610","BK4585","BK4566","BK4588","BK4561","IE00BJTD4V19.USD","BK4209","HST","IE00BFSS7M15.SGD","LU2279689827.SGD","LU1035773651.USD","BK4218","IE00BJJMRX11.SGD","LU0868494708.USD","LU2347655156.SGD","LU2347655073.USD","LU1430594728.SGD","BK4581","LU0795875169.SGD","LU0417517546.SGD","LU1244550494.USD","BK4550","BK4539","LU0256863811.USD","IE00BJJMRY28.SGD","LU0868494617.USD","LU0912757837.SGD","IE00BJTD4N35.SGD","LU0942090050.USD","MCD","BK4144","LU1069347547.HKD","BK4181"],"gpt_icon":0},{"id":"2576272059","title":"Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2576272059","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576272059?lang=en_us&edition=fundamental","pubTime":"2025-10-17 21:12","pubTimestamp":1760706720,"startTime":"0","endTime":"0","summary":"BRISBANE, Calif., Oct.  17, 2025  (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treat","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/17/3168657/0/en/Vera-Therapeutics-Announces-ORIGIN-3-Late-Breaking-Abstract-Selected-as-Featured-Oral-Presentation-at-Opening-Plenary-Session-of-ASN-Kidney-Week-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TACI","BK4539","IE0004445015.USD","LU0795875169.SGD","LU2133065610.SGD","LU0868494617.USD","LU0256863811.USD","IE00BJTD4V19.USD","BK4534","IE00BFSS8Q28.SGD","LU1244550577.SGD","LU0417517546.SGD","LU1074936037.SGD","LU1718418525.SGD","BK4588","LU1732799900.SGD","IE00B7KXQ091.USD","LU2347655156.SGD","IE00BFSS7M15.SGD","LU1430594728.SGD","IE00BJTD4N35.SGD","MCD","LU1069347547.HKD","BK4581","LU1244550221.USD","IE00BJJMRX11.SGD","LU0726765562.USD","BK4610","LU0942090050.USD","BK4504","LU2347655073.USD","LU1244550494.USD","LU1732800096.USD","LU1035773651.USD","BK4139","LU0912757837.SGD","LU0868494708.USD","VERA","BK4566","IE00BJJMRY28.SGD","BK4585","FSGS","LU0795875086.SGD","LU2279689827.SGD","BK4550","BK4209","LU1585245621.USD"],"gpt_icon":0},{"id":"2571336480","title":"Dimerix's Drug Candidate to Treat Kidney Disease Receives Orphan Drug Designation in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2571336480","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571336480?lang=en_us&edition=fundamental","pubTime":"2025-09-30 07:49","pubTimestamp":1759189755,"startTime":"0","endTime":"0","summary":"Dimerix  said its drug candidate, DMX-200, for the treatment of focal segmental glomerulosclerosis , a serious and rare disease that attacks the kidney, has received Orphan Drug designation in Japan, according to a Tuesday filing with the Australian bourse.Japanese partner FUSO Pharmaceutical Industries has exclusive rights to develop, register, and commercialize DMX-200 to treat FSGS in the Japanese market.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DXB.AU","BK7501","FSGS","BK7508","BK7067"],"gpt_icon":0},{"id":"2564393460","title":"ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression","url":"https://stock-news.laohu8.com/highlight/detail?id=2564393460","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564393460?lang=en_us&edition=fundamental","pubTime":"2025-09-03 19:55","pubTimestamp":1756900500,"startTime":"0","endTime":"0","summary":"ZyVersa is developing Cholesterol Efflux MediatorVAR 200 to mediate removal of damaging excess cholesterol and other lipids from the kidneys’ filtration system. VAR 200 directly removes lipids from ki","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/03/3143489/0/en/ZyVersa-Therapeutics-Highlights-Lipidomic-Data-in-Alport-Syndrome-and-DKD-Reinforcing-the-Need-for-Drugs-to-Attenuate-Damaging-Renal-Lipid-Accumulation-to-Mitigate-Disease-Progress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","FSGS","BK4139","ZVSA","BK4007","BK4539"],"gpt_icon":0},{"id":"2564893114","title":"Dimerix's Market Value Falls Despite Full Funding, Record Licensing Deal, Euroz Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2564893114","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564893114?lang=en_us&edition=fundamental","pubTime":"2025-09-01 13:13","pubTimestamp":1756703593,"startTime":"0","endTime":"0","summary":"Dimerix  remained fully funded and in its strongest position to date, yet its market value has fallen by AU$18 million since its record AU$940 million US licensing agreement, Euroz Hartleys said in a report on Monday.Despite receiving AU$48 million in upfront cash and securing up to AU$1.4 billion in potential licensing value across four agreements, the company's shares remain unchanged at around AU$0.45, the same level as a year ago, the broker noted, Euroz said.The company holds enough cash to complete its Phase 3 clinical trial for focal segmental glomerulosclerosis , a rare kidney disease, and could receive up to AU$119 million in development milestone payments and AU$56 million on first US sales within 18 months, along with additional milestone payments from other regions, Euroz added.While the clinical trial risks are still present, the regulatory environment in the US has likely improved, the firm observed.The firm maintained Dimerix's speculative buy rating and its AU$1.68 pric","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","BK7508","DXB.AU","FSGS","BK7067"],"gpt_icon":0},{"id":"2563057684","title":"FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari","url":"https://stock-news.laohu8.com/highlight/detail?id=2563057684","media":"Benzinga_recent_news","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563057684?lang=en_us&edition=fundamental","pubTime":"2025-08-29 00:40","pubTimestamp":1756399200,"startTime":"0","endTime":"0","summary":"FDA eases REMS labeling for Travere's Filspari, reducing liver monitoring and removing embryo-fetal toxicity rules, with FSGS approval review ongoing.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/08/28/Doctor-Utilizing-Advanced-Digital-Tablet.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/08/28/Doctor-Utilizing-Advanced-Digital-Tablet.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/fda/25/08/47393162/fda-eases-monitoring-burden-for-kidney-disease-patients-on-travere-therapeutics-filspari","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/25/08/47393162/fda-eases-monitoring-burden-for-kidney-disease-patients-on-travere-therapeutics-filspari","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["EFT","BK4139","BK4007","FSGS","BK4539","LENZ"],"gpt_icon":0},{"id":"2559462489","title":"Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2559462489","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559462489?lang=en_us&edition=fundamental","pubTime":"2025-08-13 04:01","pubTimestamp":1755028860,"startTime":"0","endTime":"0","summary":"MZE782 Phase 1 Trial in Healthy Volunteers to Provide Proof of Mechanism Data for Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) Expected in Q3 2025 MZE829 Phase 2 HORIZON Trial Actively Enrol","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/12/3132101/0/en/Maze-Therapeutics-Reports-Second-Quarter-2025-Financial-Results-and-Recent-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FSGS","MAZE","BK4007"],"gpt_icon":0},{"id":"2555833451","title":"Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2555833451","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555833451?lang=en_us&edition=fundamental","pubTime":"2025-07-31 19:05","pubTimestamp":1753959900,"startTime":"0","endTime":"0","summary":"Received U.S. FDA approval for EMPAVELI (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGNAnnouncedcapped royalty purchase agreement with Sobi under which Apelli","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/31/3124861/0/en/Apellis-Pharmaceuticals-Reports-Second-Quarter-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0081259029.USD","LU0127658192.USD","LU1303367103.USD","LU1988902786.USD","LU2458330243.SGD","BK4081","LU0642271901.SGD","LU1880398471.USD","LU1951198990.SGD","LU2264538146.SGD","LU2098885051.SGD","BK4554","LU0823434740.USD","LU1923623000.USD","BK4529","LU2360106780.USD","BK4612","LU1852331112.SGD","BK4573","LU0109392836.USD","BK4087","IE0009356076.USD","LU1316542783.SGD","LU2250418816.HKD","LU1951200564.SGD","LU0889565833.HKD","CHMP","LU0056508442.USD","EMA","IE00BMPRXN33.USD","BK4512","LU0198837287.USD","LU1064131342.USD","BK4585","IE00B5949003.HKD","LU1880398554.USD","LU1803068979.SGD","LU1989764664.SGD","BK4605","LU0082616367.USD","LU2054465674.USD","LU2458330169.SGD","LU0823421333.USD","IE00BMPRXR70.SGD","BK4614","BK4532","FSGS","LU0390134368.USD","IE0004445239.USD"],"gpt_icon":1},{"id":"2549544383","title":"ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2549544383","media":"GlobeNewswire","labels":["productRelease","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549544383?lang=en_us&edition=fundamental","pubTime":"2025-07-08 19:52","pubTimestamp":1751975520,"startTime":"0","endTime":"0","summary":"ApoCII amyloidosis, resulting from abnormal organ deposition of toxic fibrillar amyloid proteins, is an ultra-rare condition that mostly affects the kidneys and manifests with protein spillage into th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/08/3111633/0/en/ZyVersa-Therapeutics-Supports-FDA-Authorized-Emergency-Compassionate-Use-of-Cholesterol-Efflux-Mediator-VAR-200-in-a-Patient-with-ApoCII-Amyloidosis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FSGS","BK4539","BK4007","LENZ","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ftportfolios.com/Retail/Etf/EtfSummary.aspx?Ticker=RNSC","stockEarnings":[{"period":"1week","weight":0.0131},{"period":"1month","weight":0.0129},{"period":"3month","weight":-0.0214},{"period":"6month","weight":0.0828},{"period":"1year","weight":-0.019},{"period":"ytd","weight":0.0493}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"The fund will normally invest at least 90% of its net assets in the securities that comprise the index. The index is designed to select dividend-paying securities issued by small capitalization U.S. companies.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.021133},{"month":2,"riseRate":0.5,"avgChangeRate":-0.004204},{"month":3,"riseRate":0.375,"avgChangeRate":-0.03483},{"month":4,"riseRate":0.625,"avgChangeRate":0.009437},{"month":5,"riseRate":0.75,"avgChangeRate":0.013212},{"month":6,"riseRate":0.625,"avgChangeRate":0.006859},{"month":7,"riseRate":0.777778,"avgChangeRate":0.035512},{"month":8,"riseRate":0.444444,"avgChangeRate":-0.00714},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.018023},{"month":10,"riseRate":0.555556,"avgChangeRate":0.003251},{"month":11,"riseRate":0.888889,"avgChangeRate":0.051039},{"month":12,"riseRate":0.555556,"avgChangeRate":-0.004181}],"exchange":"NASDAQ","name":"First Trust SMID Growth Strength ETF","nameEN":"First Trust SMID Growth Strength ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"First Trust SMID Growth Strength ETF(FSGS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest First Trust SMID Growth Strength ETF(FSGS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"First Trust SMID Growth Strength ETF,FSGS,First Trust SMID Growth Strength ETF股票,First Trust SMID Growth Strength ETF股票老虎,First Trust SMID Growth Strength ETF股票老虎国际,First Trust SMID Growth Strength ETF行情,First Trust SMID Growth Strength ETF股票行情,First Trust SMID Growth Strength ETF股价,First Trust SMID Growth Strength ETF股市,First Trust SMID Growth Strength ETF股票价格,First Trust SMID Growth Strength ETF股票交易,First Trust SMID Growth Strength ETF股票购买,First Trust SMID Growth Strength ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"First Trust SMID Growth Strength ETF(FSGS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest First Trust SMID Growth Strength ETF(FSGS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction